Simcere, Merck deal

The partners amended a 2011 JV under which the companies were commercializing a combined portfolio of off-patent cardiovascular and metabolic drugs. In a joint statement,

Read the full 257 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE